by Kelley Tracy | Apr 11, 2023 | Uncategorized
Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That It Has Been Awarded a Phase II SBIR From the NIH (NIAID) entitled “Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle”...
by Kelley Tracy | Feb 3, 2023 | Uncategorized
Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That a Tau Self-Association Inhibitor Designed and Prepared in its Laboratories Has Achieved First in Human Dosing Doylestown, PA. February 3, 2023 – FCTDI (formerly...
by Kelley Tracy | Jan 1, 2023 | Uncategorized
Fox Chase Chemical Diversity Center Announces it is Changing its Name to Fox Chase Therapeutics Discovery Inc Doylestown, PA. January 1, 2023 – Fox Chase Chemical Diversity Center, Inc. is changing its name to Fox Chase Therapeutics Discovery, Inc. to reflect a...
by Kelley Tracy | Aug 24, 2022 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Licensed a Platform to VeraDermics, Inc. for the Treatment of Molluscum Contagiosum and Related Pox-Virus Diseases Doylestown, PA. August 24, 2022 – FCCDC is pleased to announce that a small-molecule...
by Kelley Tracy | Jun 21, 2022 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Entitled “Optimizing a Stapled-Peptide that Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis” (R42AI170552) Doylestown, PA. June 21, 2022 – FCCDC is pleased to...
